Supplementary Table 1. TEAEs (safety analysis set)

Event, n (%)		**Regorafenib 72 mg/m^2 concomitant with VI (n=2)**	**Regorafenib 72 mg/m^2 sequential with VI (n=6)**	**Regorafenib 82 mg/m^2 sequential with VI (n=13)**	**Total (N=21)**
Any TEAE		2 (100)	6 (100)	13 (100)	21 (100)
Treatment-related AEs					
Any		2 (100)	6 (100)	13 (100)	21 (100)
Regorafenib		2 (100)	6 (100)	11 (85)	19 (91)
Irinotecan		2 (100)	6 (100)	12 (92)	20 (95)
Vincristine		2 (100)	6 (100)	9 (69)	17 (81)
Worst grade	Grade 1	0	0	2 (15)	2 (10)
	Grade 2	0	0	0	0
	Grade 3	0	3 (50)	8 (62)	11 (52)
	Grade 4	2 (100)	3 (50)	3 (23)	8 (38)
Leading to dose modification		2 (100)	6 (100)	10 (77)	18 (86)
Leading to discontinuation of study drug					
Any		1 (50)	0	2 (15)	3 (14)
Regorafenib		0	0	1 (8)	1 (5)
Irinotecan		0	0	2 (15)	2 (10)
Vincristine		1 (50)	0	1 (8)	2 (10)
Any TESAE		2 (100)	2 (33)	4 (31)	8 (38)

TEAE, treatment-emergent adverse event; TESAE, treatment-emergent serious adverse event; VI, vincristine and irinotecan.